Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Case Reports
. 2015 Feb-Mar;38(2):77-9.
doi: 10.1097/CJI.0000000000000070.

Peripheral neuropathy associated with ipilimumab: a report of 2 cases

Iyavut Thaipisuttikul  1 , Paul Chapman, Edward K Avila
Affiliations
Case Reports

Peripheral neuropathy associated with ipilimumab: a report of 2 cases

Iyavut Thaipisuttikul et al. J Immunother. 2015 Feb-Mar.

Abstract

Ipilimumab, a monoclonal antibody targeting human cytotoxic T-lymphocyte-associated antigen 4, was approved by the FDA and European Medicines Agency for the treatment of metastatic melanoma. Immune-related adverse effects can occur with the use of this agent, but peripheral nervous system problems are rare. We report 2 cases of ipilimumab-induced polyneuropathy.

PubMed Disclaimer

Conflict of interest statement

Conflict of Interest: Dr. Thaipisuttikul has no conflict of interest

Dr. Chapman has no conflict of interest

Dr. Avila has no conflict of interest

Figures

Figure 1
Figure 1
Phenotypical changes in CD4+PD-1+, CD4+ICOShi, CD8+PD-1+ T cells, CD4+CD25+FOXP3+ T cells from time point day 53, 99 and 106. Representative dot plots showed CD4+PD-1+, CD4+ICOShi (1A), CD8+PD-1+ T-cells (1B), CD4+CD25+FOXP3+ (1C). 1D. Compilation of data showing the changes during the treatment from day 53 to 106.
Figure 2
Figure 2
There are very few CD19+ B cells detected in the cerebrospinal fluid. Representative dot plot showed the CD3 and CD19 staining on CSF from day 99.
Figure 3
Figure 3
Cytokine changes in TNF-alpha, IL-5, IL-8, IL-10, IL-13 and IL-17 in case 1 at day 53, 99, 106.
See this image and copyright information in PMC

References

    1. Hodi FS, O’Day SJ, McDermott DF, et al. Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med. 2010;363:711–723. - PMC - PubMed
    1. Robert C, Thomas L, Bondarenko I, et al. Ipilimumab plus dacarbazine for previously untreated metastatic melanoma. N Engl J Med. 2011;364:2517–2526. - PubMed
    1. Kaehler KC, Piel S, Livingstone E, et al. Update on immunologic therapy with anti-CTLA-4 antibodies in melanoma: identification of clinical and biological response patterns, immune-related adverse events, and their management. Semin Oncol. 2010;37:485–498. - PubMed
    1. Wilgenhof S, Neyns B. Anti-CTLA-4 antibody-induced Guillain-Barre syndrome in a melanoma patient. Ann Oncol. 2011;22:991–993. - PubMed
    1. Liao B, Shroff S, Kamiya-Matsuoka C, et al. Atypical neurological complications of ipilimumab therapy in patients with metastatic melanoma. Neuro Oncol. 2014;16:589–593. - PMC - PubMed

Publication types

MeSH terms